16.37 0.55 (3.48%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 21.6 | 1-year : | 24.22 |
Resists | First : | 18.5 | Second : | 20.73 |
Pivot price | 16.17 | |||
Supports | First : | 14.88 | Second : | 12.38 |
MAs | MA(5) : | 15.57 | MA(20) : | 16.51 |
MA(100) : | 18.77 | MA(250) : | 21.22 | |
MACD | MACD : | -0.9 | Signal : | -1 |
%K %D | K(14,3) : | 29.2 | D(3) : | 16.3 |
RSI | RSI(14): 42.6 | |||
52-week | High : | 29.51 | Low : | 14.88 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SIBN ] has closed below upper band by 43.4%. Bollinger Bands are 1.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 16.87 - 16.93 | 16.93 - 17 |
Low: | 16.05 - 16.12 | 16.12 - 16.19 |
Close: | 16.26 - 16.38 | 16.38 - 16.5 |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Fri, 29 Mar 2024
SI-BONE (NASDAQ:SIBN) Receives New Coverage from Analysts at Piper Sandler - Defense World
Fri, 29 Mar 2024
Critical Contrast: Presbia (OTCMKTS:LENSF) vs. SI-BONE (NASDAQ:SIBN) - Defense World
Thu, 28 Mar 2024
Peeling Back The Layers: Exploring SI-BONE Through Analyst Insights - Markets Insider
Thu, 28 Mar 2024
SI-BONE (NASDAQ:SIBN) Shares Gap Up to $15.82 - MarketBeat
Thu, 14 Mar 2024
Si-Bone executive sells over $56,000 in company stock By Investing.com - Investing.com
Thu, 29 Feb 2024
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 41 (M) |
Shares Float | 38 (M) |
Held by Insiders | 2.4 (%) |
Held by Institutions | 97.9 (%) |
Shares Short | 2,320 (K) |
Shares Short P.Month | 1,750 (K) |
EPS | -1.13 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 4.15 |
Profit Margin | -31.3 % |
Operating Margin | -32.2 % |
Return on Assets (ttm) | -15.2 % |
Return on Equity (ttm) | -32.4 % |
Qtrly Rev. Growth | 21.6 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 3.38 |
EBITDA (p.s.) | -1.02 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -19 (M) |
Levered Free Cash Flow | -12 (M) |
PE Ratio | -14.49 |
PEG Ratio | -1.8 |
Price to Book value | 3.93 |
Price to Sales | 4.83 |
Price to Cash Flow | -35.93 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |